Patent claims

1. The use of N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C_{6-18})arylsulfonamides, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, in the preparation of a medicament for the treatment of a disorder mediated by the action of steroid sulfatase.

2. The use of claim 1, wherein an N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C_{6-18})arylsulfonamide is a compound of formula



I

wherein

R_1 is unsubstituted (C_{6-18})aryl, or (C_{6-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-6})alkyl,

R_2 is (C_{1-12})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{3-6})cycloalkyl(C_{1-6})alkylcarbonyl or unsubstituted (C_{6-18})aryl, or (C_{6-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-6})alkyl, and

EITHER

- R_3, R_4 and R_5 are hydrogen

OR

- R_3 and R_5 together are (C_{1-4})alkylene and R_4 is hydrogen.

3. A compound of formula



II

wherein

R_1 is unsubstituted (C_{6-18})aryl, or (C_{6-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-6})alkyl,

R_2` is (C_{1-12})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{3-6})cycloalkyl(C_{1-6})alkylcarbonyl or unsubstituted (C_{6-18})aryl, or (C_{6-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-6})alkyl,

R_3 and R_5 together are (C_{1-4})alkylene, and

R_4 is hydrogen.

4. A compound of formula



III

wherein

R_1 is unsubstituted (C_{6-18})aryl, or (C_{6-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-6})alkyl, and

R_2`` is (C_{1-12})alkoxycarbonyl, (C_{3-6})cycloalkyl(C_{1-6})alkylcarbonyl, unsubstituted (C_{6-18})aryl, or (C_{6-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-6})alkyl.

5. A compound of formula II, which is N-(3-thia-5,11-diaza-tricyclo[6.2.1.0*2,6*]undeca-2(6),4-dien-4-yl)-benzenesulfonamide, or a compound of formula III, which is selected from the group consisting of

- 2-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
- 2-[2-(2,3-Dichloro-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
- 2-[2-(3,5-Dichloro-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
- 2-(3,5-Bis-trifluoromethyl-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester,
- 2-(2,3-Dichloro-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester,
- 2-(3,5-Dichloro-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester, and

- N-[5-(2-Cyclopentyl-acetyl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-yl]-3,5-bis-trifluoro-methyl-benzenesulfonamide.

6. A compound according to any one of claims 4 or 5 of formula



III_{A1}

7. A compound of any one of claims 3 to 6 in the form of a salt.

8. A compound of any one of claims 3 to 7 for use as a pharmaceutical.

9. A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of any one of claims 3 to 7 in association with at least one pharmaceutically acceptable excipient.

10. A method of treating disorders mediated by the action of steroid sulfatase comprising administering a therapeutically effective amount of an N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C_{6-18})arylsulfonamide, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, to a subject in need of such treatment.

11. A compound of formula



IV

wherein X has the meaning of R_2`` in claim 4, or
a compound of formula



VI

wherein X has the meaning of R_2` as defined in claim 3, or

a compound of formula



VII

wherein R_1 is as defined in claim 2.